← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 Metabolic Reprogramming to Reverse Senescence (SIRT1,PGC1A,NAMPT) — 1.00 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.99 TREM2-Dependent Microglial Senescence Transition (TREM2) — 0.95 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.95 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.94 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 (CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes) — 0.94 Multi-Biomarker Composite Index Surpassing Amyloid PET for T (COMPOSITE_BIOMARKER) — 0.93 Closed-loop focused ultrasound targeting CA1 PV interneurons (PVALB) — 0.93 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.92 CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli (CYP46A1) — 0.92 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Selective Acid Sphingomyelinase Modulation Therapy (SMPD1) — 0.92 HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM (HK2) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92 CYP46A1 Overexpression Gene Therapy (CYP46A1) — 0.92 Chromatin Remodeling-Mediated Nutrient Sensing Restoration (SMARCA4) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 SASP-Mediated Complement Cascade Amplification (C1Q/C3) — 0.91 TREM2-ASM Crosstalk in Microglial Lysosomal Senescence (SMPD1) — 0.91 TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene (TREM2) — 0.91 Nutrient-Sensing Epigenetic Circuit Reactivation (SIRT1) — 0.91 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 0.90 CSF1R Inhibition-Mediated Microglial Replacement as a State (CSF1R) — 0.90 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 0.90 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.90 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.89
Add
|
× SASP Modulation Rather Th
NFKB1,IL1B,BDNF · - · therapeutic
Composite 0.981
Price $0.97
Evidence For 0
Evidence Against 0
## Mechanistic Overview
SASP Modulation Rather Than Cell Elimination starts from the claim that modulating NFKB1,IL1B,BDNF within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "# SASP Modulation Rather Than Cell Elimination ## Hypothesis Expansion: Selectively Modulating the Senescence-Associated Secretory Phenotype Through NF-κB and Cytokine Pathway Targeting to Reduce Neurotoxic Inflammation While Preserving Neurotrophic Funct
Radar Chart — 10 Dimensions
Score Breakdown
Dimension SASP Modulation Rather Than Ce Mechanistic 0.700 Evidence 0.710 Novelty 0.700 Feasibility 0.800 Impact 0.780 Druggability 0.800 Safety 0.800 Competition 0.600 Data 0.700 Reproducible 0.700 KG Connect 0.957
Evidence SASP Modulation Rather Than Cell Elimination No evidence citations yet
Price History Overlay
Knowledge Graph Comparison
SASP Modulation Rather Than Cell Elimina
68 edges
Top Node Types gene 57
disease 6
drug 3
pathway 2
Top Relations co_discussed 54
investigated_in 7
activates 3
associated_with 2
contributes_to 1